新生血管性年龄相关性黄斑变性患者对玻璃体腔注射阿柏西普无应答的特征
该回顾性干预性连续病例系列研究纳入365例接受3次每月玻璃体腔注射阿柏西普且随访至少12个月的治疗初治新生血管性AMD患者,评估解剖学应答。19眼(5.2%)为无应答者,无应答与吲哚菁绿血管造影显示的脉络膜血管高渗透性及光学相干断层扫描上视网膜下高反射物质频率较低显著相关。对无应答者追加雷珠单抗或PDT联合阿柏西普治疗在15/19眼(79%)中有效。
要点
- 365眼中19眼(5.2%)对阿柏西普无应答。
- 无应答与脉络膜血管高渗透性显著相关。
- 追加雷珠单抗或PDT联合治疗在15/19眼(79%)有效。
核心结论
- 玻璃体腔注射阿柏西普对大多数初治AMD病例有效,但小部分脉络膜血管高渗透性患者可能无应答。
研究设计与样本
- 回顾性、干预性、连续病例系列,纳入365例患者的365眼,接受3次每月玻璃体腔注射阿柏西普并随访至少12个月。
主要发现
- 19/365眼(5.2%)被确定为无应答者,其余为应答者。
- 无应答组与吲哚菁绿血管造影显示的脉络膜血管高渗透性显著相关。
- 无应答组与光学相干断层扫描上视网膜下高反射物质频率较低显著相关。
- 基线及3次每月注射后中心脉络膜厚度在无应答组倾向于较应答组更厚,但差异未达统计学显著性(分别为p=0.066和p=0.051)。
- 追加玻璃体腔雷珠单抗或PDT联合阿柏西普治疗在19例无应答者中的15例(79%)有效。
关键数值与推荐
- 应答者定义为3个月时渗出完全消退(包括视网膜内水肿、视网膜下液和色素上皮脱离)或中心视网膜厚度较基线下降超过100 µm。
- 无应答者定义为渗出增加或中心视网膜厚度下降小于100 µm。
临床怎么用
- 对阿柏西普治疗初治AMD患者,3个月时可评估解剖学应答。
- 无应答者可考虑追加雷珠单抗或PDT联合阿柏西普治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the frequency and patient characteristics that influence anatomic response of intravitreal aflibercept in treatment-naïve neovascular age-related macular degeneration (AMD). DESIGN: Retrospective, interventional, consecutive case series. METHODS: Three hundred and sixty-five eyes of 365 patients with AMD who underwent 3 monthly intravitreal aflibercept treatments with follow-up for at least 12 months were investigated. Treatment response was evaluated as follows. Responders were defined as those with complete resolution of exudation, including intraretinal oedema, subretinal fluid and pigment epithelial detachment, or more than a 100 µm decrease of central retinal thickness at 3 months compared with baseline. Non-responders were defined as patients exhibiting an increase in exudation or a decreased central retinal thickness of less than 100 µm. RESULTS: Nineteen (5.2%) of 365 eyes were identified as non-responders. The remaining were responders to intravitreal aflibercept. The non-responders group was significantly associated with choroidal vascular hyperpermeability on indocyanine green angiography and lower frequency of subretinal hyper-reflective materials on optical coherence tomography. The central choroidal thickness at baseline and after 3 monthly injections tended to be thicker in the non-responder group than the responder group, although the differences did not meet statistical significance (p=0.066 and p=0.051, respectively). Additional treatments with either intravitreal ranibizumab or PDT in combination with aflibercept were effective in 15 (79%) of 19 non-responders. CONCLUSION: Intravitreal aflibercept is effective for treating eye pathology in most naïve AMD cases. However, non-responsiveness may occur in small subgroup of patients with choroidal vascular hyperpermeability.
引用
- Hara C, Wakabayashi T, Toyama H, et al. Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept. Br J Ophthalmol. 2018. PMID: 29907628. doi:10.1136/bjophthalmol-2018-312275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。